Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer

ABSTRACT There is an unmet need to predict immune‐related adverse events (irAEs) in patients receiving immune checkpoint inhibitors. This study aimed to examine whether eosinophils can predict irAEs in metastatic urothelial carcinoma (mUC). In this multicenter cohort study, we retrospectively examin...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Kunihiro Odagiri, Yoshihiko Tasaki, Taku Naiki, Toshiharu Morikawa, Keitaro Iida, Yusuke Noda, Rika Banno, Teruki Isobe, Nobuhiko Shimizu, Maria Aoki, Yoshihisa Mimura, Yosuke Sugiyama, Takashi Nagai, Toshiki Etani, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Yoko Furukawa‐Hibi, Takahiro Yasui
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wiley 2026-07-01
سلاسل:	Cancer Medicine
الموضوعات:	bladder cancer eosinophil immune‐related adverse event pembrolizumab urothelial carcinoma
الوصول للمادة أونلاين:	https://doi.org/10.1002/cam4.72072
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!